Male study dosing
1–12 mg once weeklyRange studied in the Phase 2 trial
SIX VIALS · ONE HOLDERMGMT RESEARCH
GASSED UP BUNDLES · METABOLIC RESEARCH
AFTERBURN
Ultimate Research Stack
The full grid: two TESAROSSA (Tesamorelin) 20 mg vials, one RETROD (Retatrutide) 20 mg vial, and three BAC Water 3 mL vials. Organized in one white six-slot vial holder, with 10% off the combined individual price.
$513.00 CAD$570.00 CAD separately · Save $57.00 CAD (10%) · Six-slot holder included
INCLUDED3 compound vials · 3 water vials · 1 six-slot holder
01 / TESAROSSA2 × 20 mg vials
02 / RETROD1 × 20 mg vial
03 / BAC WATER3 × 3 mL vials
04 / HOLDEROne six-slot holder
COAs pending for RETROD and TESAROSSA. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario.
BAC Water promotion +
AFTERBURN is excluded from the BAC Water promotion because it is already discounted by 10%. Each pack includes three BAC Water vials, with no additional promotional water. Separately purchased eligible compound vials still qualify.
Tax-inclusive CAD pricing. E-transfer accepted · Credit cards coming soon.
Read AFTERBURN | The Powerful Fat Loss Stack explained →
BUNDLE OVERVIEWSix vials.
Six vials.
One complete collection.
AFTERBURN includes two TESAROSSA 20 mg vials, one RETROD 20 mg vial, three BAC Water 3 mL vials, and one white six-slot holder. The compounds remain in separate vials.
Individual prices & bundle savings +
- TESAROSSA · Tesamorelin 20 mg
- 2 vials × $180.00 CAD = $360.00 CAD
- RETROD · Retatrutide 20 mg
- 1 vial × $180.00 CAD = $180.00 CAD
- BAC Water · Bacteriostatic Water 3 mL
- 3 vials × $10.00 CAD = $30.00 CAD
- White six-slot vial holder
- 1 holder · included at no extra charge
- Combined individual total
- $570.00 CAD
- 10% bundle discount
- −$57.00 CAD
- AFTERBURN bundle price
- $513.00 CAD
Six-slot holder layout +
- Front row
- RETROD 20 mg + TESAROSSA 20 mg + BAC Water 3 mL
- Back row
- TESAROSSA 20 mg + BAC Water 3 mL + BAC Water 3 mL
The holder organizes all six supplied vials in two rows of three. It does not provide temperature control.
RETROD · 1 vial · 20 mg each
RETROD / research information
Female study dosing
1–12 mg once weeklyRange studied in the Phase 2 trial
Frequency in trials
Once weeklyClinical study schedule
Route in trials
SubcutaneousInvestigational administration
Reported half-life
Approximately 6 daysHuman pharmacokinetic research
Post-cycle PCT
Not establishedNo validated PCT protocol
Phase 2 trial arms: 1, 4, 8, and 12 mg once weekly. These study doses were not separate male/female recommendations or directions for using MGMT Research vials. Published study ↗
DESCRIPTION
What is RETROD 20 mg?
RETROD is our name for Retatrutide (LY3437943), a synthetic peptide investigated for its combined activity at the GLP-1, GIP, and glucagon receptors. These pathways are involved in appetite, glucose regulation, and energy metabolism.
Each included RETROD vial contains 20 mg of labeled lyophilized compound. This is the total vial amount, not a dose or a solution concentration. RETROD is sourced through a Canadian supplier partner and is not filled in-house by MGMT Research.
COA results are pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario; verified purity and net-content figures will be published when available.
BENEFITS / RESEARCH INTERESTThree pathways.
Three pathways.
One research compound.
Retatrutide is studied for potential effects on body weight and metabolic health. These are research findings, not promised outcomes from this product.
- Appetite and body composition: weight-change endpoints in controlled studies.
- Glucose regulation: incretin and glucagon receptor signaling.
- Energy metabolism: investigation of multiple hormonal pathways together.
Product specifications & handling +
- Product
- RETROD · Retatrutide
- Selected quantity
- 20 mg
- Form
- Lyophilized powder
- Receptors
- GLP-1R · GIPR · GCGR
- Testing
- COA pending · SideChain Analytics
- Origin / dispatch
- Canadian supplier partner / Toronto
Follow batch-specific supplier instructions and your laboratory’s validated storage and reconstitution procedures. A prepared solution’s shelf life has not been established for this product.
Orders received before 12 PM EST ship the same business day.
COA pending. Purity and net-content results will be published when the batch-specific report is available.
TESAROSSA · 2 vials · 20 mg each
TESAROSSA / research information
Male study dosing
2 mg once dailyOriginal formulation in clinical trials
Female study dosing
2 mg once dailyOriginal formulation in clinical trials
Frequency in trials
Once dailyPublished clinical study schedule
Route in trials
SubcutaneousClinical study administration
Reported half-life
Formulation-dependent8 minutes reported for EGRIFTA SV
Post-cycle PCT
Not establishedNo validated PCT protocol
The original Tesamorelin trials used 2 mg once daily in adults with HIV-associated abdominal fat accumulation, without separate male/female regimens. These are study details, not directions for TESAROSSA vials. Published study ↗ · Formulation-specific pharmacokinetics ↗
DESCRIPTION
What is TESAROSSA 20 mg?
TESAROSSA is our name for Tesamorelin, a synthetic growth hormone–releasing hormone (GHRH) analogue. It acts through the GHRH receptor to stimulate endogenous growth hormone release and downstream IGF-1 signaling.
Each included TESAROSSA vial contains 20 mg of labeled lyophilized compound. This is the total vial amount, not a dose or a solution concentration. TESAROSSA is sourced through a Canadian supplier partner and is not filled in-house by MGMT Research.
COA results are pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario; verified purity and net-content figures will be published when available.
BENEFITS / RESEARCH INTERESTThe GHRH pathway.
The GHRH pathway.
A focused research profile.
Tesamorelin research explores growth hormone signaling and body composition, including visceral adipose tissue in HIV-associated lipodystrophy. Findings concern studied pharmaceutical formulations, not promised outcomes from TESAROSSA.
- Visceral adipose tissue: abdominal fat endpoints in controlled studies.
- GH / IGF-1 signaling: endocrine responses to GHRH receptor activation.
- Metabolic markers: lipid and glucose measures assessed in clinical research.
Product specifications & handling +
- Product
- TESAROSSA · Tesamorelin
- Selected quantity
- 20 mg
- Form
- Lyophilized powder
- Receptors
- GHRH receptor / GH–IGF-1 axis
- Testing
- COA pending · SideChain Analytics
- Origin / dispatch
- Canadian supplier partner / Toronto
Follow batch-specific supplier instructions and your laboratory’s validated storage and reconstitution procedures. A prepared solution’s shelf life has not been established for this product.
Orders received before 12 PM EST ship the same business day.
COA pending. Purity and net-content results will be published when the batch-specific report is available.
BAC WATER · 3 vials · 3 mL each
BAC Water / diluent information
Vial volume
3 mLOne vial of BAC Water
Product form
LiquidReady as a research diluent
Primary role
Diluent / solventCompatible preparation protocols
Preservative
Label-specifiedCheck your supplied product label
Volume to add
Protocol-dependentNo universal reconstitution volume
Intended use
Laboratory researchCompatible non-human protocols
The 3 mL label states the volume supplied. It does not mean that every research vial requires 3 mL of diluent.
DESCRIPTIONWhat is
What is
BAC Water?
Bacteriostatic water is water formulated with a preservative, commonly benzyl alcohol, to inhibit bacterial growth. It differs from preservative-free sterile water. Refer to the supplied product label for its exact formulation, preservative concentration, expiry, and storage instructions.
It serves as a diluent or solvent to dissolve a compatible dry material or dilute an existing solution. In laboratory peptide research, reconstitution means adding an appropriate diluent to lyophilized powder to prepare a solution for a specified procedure.
AFTERBURN includes three separate 3 mL BAC Water vials, totaling 9 mL.
LABORATORY APPLICATIONSA compatible diluent.
A compatible diluent.
A clear calculation.
- Reconstitution: prepare a solution from compatible lyophilized material.
- Dilution: adjust concentration according to your research protocol.
- Measurement: use Mix Easy to calculate concentration and sample volume.
Product specifications & shipping +
- Product
- BAC Water · Bacteriostatic Water
- Vial volume
- 3 mL
- Format
- Liquid
- Presentation
- 3 separate vials · 3 mL per vial
- Intended use
- Laboratory research
- Dispatch
- Toronto, Ontario
Follow the storage instructions and expiry printed on your supplied vial. Orders received before 12 PM EST ship the same business day.
MIX EASYYour mixture.
Your mixture.
Made clear.
Select your compound, vial amount, diluent volume, and sample amount. Our calculator converts your inputs into a concentration, volume, and U-100 syringe marking.
01
Set your mixture
mg
mL
Enter an example amount to calculate its volume.
02
Your measurement
RETATRUTIDE
20units
0.2 mL of solution per sample
U-100 scale1 mL = 100 units
Concentration10 mg/mL
Full samples per vial5
THE CALCULATION
2 mg ÷ 10 mg/mL = 0.2 mL
How to read this calculator +
Concentration = vial amount ÷ solution volume. Sample volume = sample amount ÷ concentration. U-100 scale units = volume in mL × 100; these are volume markings, not units of compound potency.
This example assumes the final solution volume equals the diluent volume entered, and that the compound dissolves completely. It does not establish solubility, compatibility, stability, or an administration dose.
Decimal measurements are mathematical results and may fall between markings. Full samples are rounded down; they do not account for handling losses.
The calculator checks concentration mathematics. It does not select a treatment dose or establish compatibility, sterility, or stability. SEMARO is temporarily unavailable and is omitted from this selector. BAC Water is the diluent, not a peptide.
RETROD · 1 vial · 20 mg each
RETROD / research information
SIDE EFFECTS & CONSIDERATIONS
What the research reports.
In the Phase 2 study, gastrointestinal adverse events were most common and increased with dose. Heart-rate increases were also observed. Longer-term safety remains under investigation.
Retatrutide remains investigational, with no regulatory approval. Research-grade MGMT Research vials are not clinical-trial medication.
Product-specific considerations
- Independent identity, purity, and content results are pending for RETROD.
- A labeled 20 mg quantity does not establish a therapeutic dose.
- Mixing calculations cannot establish sterility, stability, or suitability for administration.
TESAROSSA · 2 vials · 20 mg each
TESAROSSA / research information
SIDE EFFECTS & CONSIDERATIONS
What the research reports.
Reported adverse reactions to pharmaceutical Tesamorelin include joint and muscle pain, injection-site reactions, and fluid retention. Important considerations include elevated IGF-1, glucose intolerance, and hypersensitivity.
Pharmaceutical formulations have specific contraindications, including active malignancy, pregnancy, and disruption of the hypothalamic–pituitary axis. TESAROSSA research vials are not interchangeable with approved EGRIFTA formulations.
Product-specific considerations
- Independent identity, purity, and content results are pending for TESAROSSA.
- A labeled 20 mg quantity does not establish a therapeutic dose.
- Mixing calculations cannot establish sterility, stability, or suitability for administration.
BAC WATER · 3 vials · 3 mL each
BAC Water / diluent information
SIDE EFFECTS & CONSIDERATIONS
Compatibility comes first.
BAC Water is not suitable for every compound. Preservative-containing and preservative-free water are different preparations; the appropriate choice depends on the material and documented procedure.
A preservative inhibits bacterial growth but does not sterilize a contaminated preparation or replace appropriate handling technique.
Before preparing a solution
- Check the supplied vial’s formulation, expiry, seal, and storage instructions.
- Confirm diluent compatibility and required volume from the compound’s documentation.
- Inspect the preparation against your protocol’s expected appearance.
RETROD · 1 vial · 20 mg each
RETROD / research information
DOSAGE GUIDELINES / STUDY CONTEXT
Vial amount is not a dose.
Each included RETROD vial is labeled 20 mg. There is no approved male or female dosing regimen for this research product.
Published Phase 2 study arms
Adults were assigned 1, 4, 8, or 12 mg once weekly for 48 weeks under a controlled protocol. These are study details, not self-use instructions.
Laboratory sample amounts and preparation procedures should come from your validated protocol. Enter those amounts into Mix Easy to check the volume calculation.
Open Mix Easy ↗Read the original trial ↗TESAROSSA · 2 vials · 20 mg each
TESAROSSA / research information
DOSAGE GUIDELINES / STUDY CONTEXT
Vial amount is not a dose.
Each included TESAROSSA vial is labeled 20 mg. The clinical information below does not establish a dosing regimen for this research product.
Published Tesamorelin study
The 2007 trial studied 2 mg once daily for 26 weeks in adults with HIV-associated abdominal fat accumulation. It used a specific clinical formulation under a controlled protocol.
Approved EGRIFTA formulations have different doses and preparation requirements. Their instructions do not transfer to TESAROSSA vials. Laboratory sample amounts and preparation procedures should come from your validated protocol.
Open Mix Easy ↗Read the original trial ↗BAC WATER · 3 vials · 3 mL each
BAC Water / diluent information
RECONSTITUTION & HANDLINGYour protocol.
Your protocol.
Your preparation volume.
The appropriate volume of BAC Water depends on the compound, required concentration, and validated research procedure. The 3 mL vial size is the volume supplied, not a universal mixing instruction.
Concentration mathematics
Compound amount ÷ final solution volume = concentration. Laboratory sample amount ÷ concentration = sample volume.
Follow the documented diluent, equipment, mixing method, and storage requirements for the material being prepared. Mix Easy assumes the entered diluent volume equals the final solution volume.
Open Mix Easy ↗Read reconstitution basics ↗Styled packaging concept shows six supplied vials in one translucent-white plastic six-slot holder. Final packaging may vary.